
21:40 ET QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

I'm PortAI, I can summarize articles.
Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations on behalf of investors in uniQure N.V. (NASDAQ: QURE). Following a press release on November 3, 2025, uniQure disclosed that the FDA deemed data for its AMT-130 gene therapy insufficient for a Biologics License Application, leading to a stock price drop of over 50%. Investors with significant losses are encouraged to contact the firm for more information.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

